INT82806

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.41
First Reported 1999
Last Reported 2006
Negated 0
Speculated 0
Reported most in Abstract
Documents 3
Total Number 3
Disease Relevance 0.58
Pain Relevance 0.37

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (ABL2) signal transduction (ABL2) protein modification process (ABL2)
cytoplasm (ABL2)
Anatomy Link Frequency
vesicle 1
ABL2 (Homo sapiens)
ABL2 - R142H (1)
Pain Link Frequency Relevance Heat
Neuropeptide 2 93.12 High High
Neurotransmitter 3 84.36 Quite High
melanocortin 1 receptor 2 75.00 Quite High
Enkephalin 1 70.32 Quite High
COX-2 inhibitor 2 5.00 Very Low Very Low Very Low
aspirin 1 5.00 Very Low Very Low Very Low
COX2 1 5.00 Very Low Very Low Very Low
withdrawal 1 5.00 Very Low Very Low Very Low
cINOD 1 5.00 Very Low Very Low Very Low
anticonvulsant 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Chronic Myeloid Leukemia 1 99.90 Very High Very High Very High
Disease 14 89.72 High High
Pox Virus Infection 5 88.16 High High
Sarcoma 4 51.20 Quite High
Infection 20 48.96 Quite Low
Cancer 2 11.76 Low Low
Acquired Immune Deficiency Syndrome Or Hiv Infection 32 10.92 Low Low
Hepatitis D Virus Infection 7 5.00 Very Low Very Low Very Low
Cytomegalovirus Infection 7 5.00 Very Low Very Low Very Low
Communicable Diseases 6 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In this review, evidence for secretory vesicle cathepsin L and Arg/Lys aminopeptidase as a distinct proteolytic pathway for processing the prohormone proenkephalin is presented.
Negative_regulation (presented) of Arg in vesicle
1) Confidence 0.41 Published 2004 Journal Biol. Chem. Section Abstract Doc Link 15255178 Disease Relevance 0 Pain Relevance 0.23
The antiviral properties that have been described for Gleevec (Imatinib mesylate), which was originally licensed for the treatment of chronic myelogenous leukemia and inhibits the Abl tyrosine kinase, exemplify the advantages of target discovery that uses both basic knowledge and the genome-scale approach.
Negative_regulation (inhibits) of Abl tyrosine kinase associated with chronic myeloid leukemia
2) Confidence 0.03 Published 2006 Journal Genome Biol Section Body Doc Link PMC1431708 Disease Relevance 0.58 Pain Relevance 0
None of the mutant receptors displayed complete loss of alphaMSH binding, with only the Arg142His and Asp294His displaying a slight reduction in binding affinity.
Negative_regulation (reduction) of Arg142His (R142H)
3) Confidence 0.00 Published 1999 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 10403794 Disease Relevance 0 Pain Relevance 0.14

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox